Proactive Investors - Run By Investors For Investors

Pressure BioSciences CEO says company poised for 'solid year' in 2018

CEO sees assets such as BaroFold, Ultra Shear taking firm 'further down the road to profitability'
Lab tech typing on laptop
The life-science group makes laboratory devices

Pressure BioSciences Inc. (OTCQB:PBIO) Chief Executive Officer Richard T. Schumacher said he expects 2018 to be “another solid year” for the Massachusetts-based company, helped in part by the acquisition of BaroFold intellectual property.

“The results we achieved in 2017 were especially rewarding in that they were achieved with only one dedicated salesperson,” Schumacher said recently on Uptick Newswire’s “Stock Day” podcast. “The enhancements we are implementing in our products, our sales and marketing capabilities, and our corporate infrastructure will allow us to better design, create, sell, support and distribute our product line in 2018.”

READ: Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business

The life-science group that makes laboratory devices said last week that fourth-quarter sales gained 20% as its product and services business continues to grow. Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The CEO also cited new patents in Pressure BioSciences’s Ultra Shear Technology platform and the release of its GMP-compliant software as areas that will contribute to results this year.

“We believe these new assets will help expand our customer base, take us further down the path to profitability and help increase shareholder value,” Schumacher said.

View full PBIO profile View Profile

Pressure BioSciences Inc. Timeline

Related Articles

Nemaura Medical Inc CEO Dr Faz Chowdhury
November 06 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use